Bristol-Myers Squibb Co 

BMY:NYSE

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
43.30 0.53   1.24%3.23%11,130,08613.2M

Market data is delayed by at least 20 minutes.
Market is closed. As of 03:59 PM ET 5/17/2013
 
 
 

Latest News Headlines for Bristol-Myers Squibb Co

Bristol-Myers Squibb Announces Intention to Voluntarily Delist Preferred Stock
1 days 12 hours 6 minutes ago - BusinessWire via Dow Jones News
NEW YORK--(BUSINESS WIRE)--May 16, 2013-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has notified the New York Stock Exchange ("NYSE") of its intention to voluntarily delist its $2 Convertible Preferred Stock (the "Preferred Stock") from the NYSE.
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
2 days 10 hours 26 minutes ago - BusinessWire via Dow Jones News
NEW YORK--(BUSINESS WIRE)--May 15, 2013-- Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference at 7 p.m. EDT (6 p.m. CDT) on Sunday, June 2, 2013, to review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of data presented at the meeting, with a focus on the immuno-oncology portfolio, and address inquiries from investors and analysts.
Bristol-Myers Squibb Advances Leadership Position -4-
2 days 10 hours 36 minutes ago - BusinessWire via Dow Jones News
fatigue (91% vs 79%), nausea (64% vs 50%), dry skin (57% vs 15%), pain-other (59% vs 37%), and constipation (53% vs 38%). The most common grade 3/4 adverse reactions (>=10%) included: fatigue (31% vs 29%),
View more recent headlines
 
 
 
 
 
 
More Filings

Latest Annual and Quarterly SEC Filings

10-K
February 15, 2013
This report contains detailed information about the company's business finances and management.
10-Q
April 25, 2013
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
 
 
 
Company Background
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in 6 foreign countries. In February 2012, it acquired Inhibitex, Inc. (Inhibitex). In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. In August 2012, Synergy Pharmaceuticals Inc announced that it signed an Asset Purchase Agreement with the Company and acquired the assets related to FV-100, an orally available nucleoside analogue, being developed for the treatment of shingles.

Bid/Size
-- / --
Ask/Size
-- / --
Price Open
42.99
Previous Close
42.77
Day High
43.43
Day Low
42.70
52wk High/Date
45.59 / 5/15/2013
52wk Low/Date
30.64 / 11/15/2012
% off 52wk High
-5.02%
% off 52wk Low
41.32%
Beta (5 Yr)
0.4
Market Capitalization
71.1B
Shares Outstanding
1.6B
Volatility Avg
19.01
EPS(TTM)
0.88
P/E Ratio
49.4x
Dividend Announcement
3/7/2013
Dividend Yield
3.23%
Ex-Date
4/3/2013
Date of Record
4/5/2013
Payable
0.35 - QRTR
Payable Date
5/1/2013
Last Trade as of 5/17/2013 4:00 PM ET
 
 
 

BMY Bristol-Myers Squibb Co vs. Peers

Peers 
BMY
Bristol-Myers Squibb Co
32.86%
Johnson & Johnson
25.66%
Pfizer Inc.
15.47%
Merck & Co., Inc.
12.34%
BMY
Bristol-Myers Squibb Co
3.23%
Johnson & Johnson
3.00%
Pfizer Inc.
3.31%
Merck & Co., Inc.
3.74%
BMY
Bristol-Myers Squibb Co
1.24%
Johnson & Johnson
0.73%
Pfizer Inc.
-0.99%
Merck & Co., Inc.
-0.82%
Compare these stocks